Pharma Merger
WILMINGTON, Del. — A federal class action claims directors are selling the biopharmaceutical company ArQule too cheaply through an unfair process to Merck Sharp & Dohme, for $20 a share or $2.7 billion.
WILMINGTON, Del. — A federal class action claims directors are selling the biopharmaceutical company ArQule too cheaply through an unfair process to Merck Sharp & Dohme, for $20 a share or $2.7 billion.